In addition to patient care and clinical research, experimental research represents the third field of activity of the Department of Anesthesiology and Surgical Intensive Care 新万博体育下载_万博体育app【投注官网】icine. In our research laboratory we work on translational and basic scientific topics in the field of pain and inhibitory neurotransmission, especially glycinergic neurotransmission. The aim is to identify novel therapeutic approaches for the treatment and/or prevention of chronic pain.???

The perception of pain represents an important warning function of the body and protects it from potential damage. Chronic inflammation, systemic disease, or lesions in the peripheral or central nervous system can lead to pathological nociceptive hyperactivity. This manifests as a spontaneous and/or excessive pain response to non-painful or mild stimuli (allodynia or hyperalgesia). Despite intensive research, these chronic forms of pain have been difficult to treat. In a significant proportion of patients, treatment success is unsatisfactory, partly due to serious side effects of the drugs used, partly due to insufficient efficacy of the respective therapies. Extensive data suggest that the chronification of pain causes neuroplastic changes within the central nervous system that lead to specific differences in the processing of chronic and acute pain. It is known that, particularly in the dorsal horn of the spinal cord, the balance of synaptic excitation and inhibition changes during the development of chronic pain, and this is likely to contributes to the pathogenesis of chronic pain. In particular, changes in glycinergic inhibition have only superficially studied and pharmacological interventions have so far been impossible or poorly feasible due to the poorly developed pharmacology of glycinergic neurotransmission.

In this project, we use multidisciplinary approaches to try to understand the mechanisms underlying neuroplastic changes involved in the establishment of chronic pain and develop novel therapeutic concepts based on them.

As a novel approach for the treatment of chronic pain, we are investigating the possibilities of enhancing glycinergic inhibition indirectly by inhibition through glycine transporters (GlyT). We are investigating the mechanisms of action of these substances and the functions of these transporters in in vitro and in vivo, using biochemical, pharmacological, electrophysiological, and mouse genetic methods.

?

Glycine is an important inhibitory neurotransmitter, but additionally functions as an essential coagonist at excitatory glutamate receptors of the N-methyl-D-aspartate (NMDAR) subtype. Regulation of extracellular glycine concentration at both synapse types occurs via glycine transport systems with high affinity and capacity that catalyze the transport of glycine across the membranes of presynaptic terminals and glial cells surrounding the synapse, respectively. Although most cells at glycine-dependent synapses express more than one transporter with high affinity for glycine, their precise function as well as their functional interaction is poorly understood. In this project, we investigate how transporters with high affinity for glycine, which are the mainly astroglially expressed glycine transporter 1 (GlyT1; SLC6A9), the both neuronally and astoglially expressed the alanine-serine-cysteine-1 transporter (ASC-1, SLC7A10), and the exclusively neuronally expressed GlyT2 (Slc6a5) interact with each other in maintaining glycine homeostasis at glycinergic synapses, and how their function changes during development.

The goal of this project is to clarify the individual contribution of glycine-specific transporters to the regulation of glycine-dependent neurotransmission. Here, we will elucidate the functions of each transporter at inhibitory synapses in order to clarify the precise mechanisms of how these transporters interact with each other for the maintenance of the glycine circuit at glycinergic synapses. We plan to undertake this project using an interdisciplinary approach that employs complex genetic and RNAi techniques in addition to biochemical and electrophysiological methods.

?